Responses
Clinical/translational cancer immunotherapy
Original research
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
Compose a Response to This Article
Other responses
No responses have been published for this article.
